Search
Obeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigationalThe NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.[L12636] … [L34650] Obeticholic acid is currently being considered for FDA approval to treat fibrosis caused by non-alcoholic liver steatohepatitis (NASH).
Cerliponase alfa
go.drugbank.com/drugs/DB13173ApprovedInvestigational[L51329] CLN2 is a predominantly pediatric-onset neurodegenerative disease caused by a deficiency in the lysosomal enzyme TPP1, leading to progressive impairment in motor and cognitive function. … Cerliponase alfa is a hydrolytic lysosomal N-terminal tripeptidyl peptidase-1 (TPP1).
Categories: Hydrolytic Lysosomal N-terminal Tripeptidyl PeptidaseEquine Botulinum Neurotoxin A Immune FAB2
go.drugbank.com/drugs/DB13900ApprovedEquine Botulinum Neurotoxin A Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype A. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A in adults and pediatric patients.
Albutrepenonacog alfa
go.drugbank.com/drugs/DB13884Approved[A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016.
Gonadorelin
go.drugbank.com/drugs/DB00644ApprovedInvestigationalVet approvedGnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary.
Gadoteric acid
go.drugbank.com/drugs/DB09132ApprovedInvestigationalassociated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood-brain barrier (BBB) and/or abnormal vascularity. … due to a decreased tendency of gadolinium dechelation.
Synonyms: [2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl-κ4N1,N4,N7,N10)tetraacetato(3−)]gadoliniumSpesolimab
go.drugbank.com/drugs/DB15626ApprovedInvestigational[A252220, A252225] Spesolimab received recommendations from the EMA's Committee for Medicinal Products for Human Use (CHMP) to be granted marketing authorization in October 2022 and was finally approved … The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares.
Atosiban
go.drugbank.com/drugs/DB09059ApprovedInvestigationalIt is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. … Atobisan was developed by the Swedish company Ferring Pharmaceuticals. It was first reported in the literature in 1985.
Agkistrodon piscivorus antivenin
go.drugbank.com/drugs/DB13894ApprovedThe cottonmouth habitat range extends from southeastern Virginia (near the junction of the Appomattox and James rivers) to southern Florida, west to central Texas, Oklahoma, Arkansas, Missouri, and southeastern … This species of snake is endemic to the United States.
Equine Botulinum Neurotoxin F Immune FAB2
go.drugbank.com/drugs/DB13901ApprovedEquine Botulinum Neurotoxin F Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype F. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes F in adults and pediatric patients.